Inhaled Corticosteroids for Outpatients with Covid-19: A Meta-Analysis

November, 2021


The role of inhaled corticosteroids for outpatient COVID-19 is evolving. We meta-analyzed reported clinical trials and estimated probability of any effect and number needed to treat of 50 or 20 for symptom resolution by day 14 [100%, 99.8%, 93.1%] and hospitalization [88.6%, 72.7%, 26.3%] respectively.

Inhaled corticosteroids are widely available, inexpensive in most jurisdictions, have few reported severe side effects and are likely beneficial based on the total evidence to date.